AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer

Days After Green Light For Clovis's Rival PARP

20 May 2020

Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.

targets — Lynparza now approved for four tumor types • Source: Shutterstock

Less than a week after Clovis Oncology Inc.'s Rubraca became the first PARP inhibitor approved for prostate cancer, AstraZeneca PLC and Merck & Co. Inc.'s class leader Lynparza has become the second, and the one observers expect to dominate the market.

The US Food and Drug Administration has approved Lynparza (olaparib) for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

China Biopharma Podcast - 14 May 2025 (Chinese Language)

14 May 2025

• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

13 May 2025

• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.